Edgewise Therapeutics, Inc. (EWTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EWTX currently has 105M outstanding shares. with moderate dilution risk from 24.4M authorized shares representing 23.1% potential dilution. The company has diluted shareholders by 14.15% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 06, 2025 |
10-Q filing | 105.5M shares outstanding |
110M | 24M |
| May 08, 2025 |
10-Q filing | 95.1M shares outstanding |
95M | 24M |
| Mar 03, 2025 |
10-K filing | 92.4M shares outstanding |
92M | 24M |
| Nov 07, 2024 |
10-Q filing | 93.8M shares outstanding |
94M | 24M |
| Aug 08, 2024 |
10-Q filing | 93.5M shares outstanding |
94M | 24M |
| May 09, 2024 |
10-Q filing | 87.6M shares outstanding |
88M | 24M |
| Feb 22, 2024 |
10-K filing | 63.7M shares outstanding |
64M | 24M |
| Nov 09, 2023 |
10-Q filing | 63.5M shares outstanding |
63M | 24M |
| Aug 10, 2023 |
10-Q filing | 63.4M shares outstanding |
63M | 24M |
| May 11, 2023 |
10-Q filing | 63.3M shares outstanding |
63M | 24M |
| Feb 23, 2023 |
10-K filing | 53.6M shares outstanding |
54M | 24M |
| Nov 03, 2022 |
10-Q filing | 63.2M shares outstanding |
63M | 24M |
| Sep 14, 2022 |
8-K filing: Edgewise Therapeutics, Inc. entered into an underwriting agreement for a public offering of 11,627,907 shares of its common stock at $10.32 per share, with an option for the underwriters to purchase an additional 1,744,186 shares, expected to close on September 16, 2022. ($120.0M proceeds) |
50M | 24M |
| Aug 04, 2022 |
10-Q filing | 49.6M shares outstanding |
50M | 24M |
| May 11, 2022 |
10-Q filing | 49.5M shares outstanding |
50M | 24M |
| Apr 01, 2022 |
S-3 filing: Edgewise Therapeutics files an S-3 shelf registration to offer common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units for an aggregate offering price of up to $400,000,000, and an ATM prospectus supplement to offer common stock for an aggregate offering price of up to $125,000,000 through Cowen and Company, LLC. |
50M | 24M |
| Feb 24, 2022 |
10-K filing | 49.5M shares outstanding |
50M | 12M |
| Nov 10, 2021 |
10-Q filing | 49.3M shares outstanding |
49M | 12M |
| Aug 09, 2021 |
10-Q filing | 49.3M shares outstanding |
49M | 12M |
| May 13, 2021 |
10-Q filing | 49.3M shares outstanding |
49M | 12M |
| Mar 24, 2021 |
S-1/A filing: This S-1/A filing details the expenses related to the offering, indemnification of directors and officers, recent sales of unregistered securities, including Series A, B-1, B-2, and C convertible preferred stock, and stock options granted to employees and service providers. |
N/A | 12M |
| Mar 22, 2021 |
S-1/A filing: Edgewise Therapeutics, Inc. is offering 10,000,000 shares of common stock in an initial public offering. The initial public offering price is expected to be between $14.00 and $16.00 per share. |
N/A | 12M |